Specialized Blood Product Modifications

The contract involves the provision of specialized blood product modifications including HLA and HPA matching, irradiation, leukoreduction, and volume reduction to meet the unique transfusion needs of vulnerable patient populations. These services are critical for patients with immunological sensitivities, chronic transfusion requirements, or compromised immune systems who require antigen-specific blood products to prevent adverse reactions and ensure clinical safety. The work is scoped to support specialized medical care within the Department of Veterans Affairs system, with all activities conducted under the 252-NETWORK Contract Office 12 (36C252). The North American Industry Classification System code 811211 indicates the performance of medical and diagnostic laboratory services, aligning with the technical precision required for blood product processing. The opportunity is structured as a subcontract with a response deadline of August 21, 2026, and was posted on July 22, 2026. There is no specified set-aside designation, and the place of performance details are not provided, suggesting flexibility in operational location as long as the required services are delivered to meet VA patient needs. All processing must adhere to strict standards for accuracy and sterility, ensuring compatibility and safety for recipients. The contract emphasizes technical expertise, regulatory compliance, and timely delivery to support life-sustaining transfusion therapies within the Veterans Health Administration.